期刊
LUNG CANCER
卷 162, 期 -, 页码 42-53出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2021.09.003
关键词
Biomarker; Molecular targeted therapy; ErbB receptors; Molecular diagnostic techniques; Adjuvant therapy; Carcinoma; non-small cell
资金
- AstraZeneca
- Good Publications Practice (GPP3)
Precision medicine in non-small cell lung cancer (NSCLC) is rapidly advancing, with targeted therapies for advanced disease being developed and molecular testing becoming increasingly important. While routine molecular testing is not currently required for stage I-III disease, recent studies have shown promising results that suggest the integration of molecular testing and targeted therapy may be beneficial for these earlier stages of NSCLC in the near future.
Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of targeted therapies for advanced disease and concomitant molecular testing to inform clinical decision-making. In contrast, routine molecular testing in stage I-III disease has not been required, where standard of care comprises surgery with or without adjuvant or neoadjuvant chemotherapy, or concurrent chemoradiotherapy for unresectable stage III disease, without the integration of targeted therapy. However, the phase 3 ADAURA trial has recently shown that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, reduces the risk of disease recurrence by 80% versus placebo in the adjuvant setting for patients with stage IB-IIIA EGFR mutation-positive NSCLC following complete tumor resection with or without adjuvant chemotherapy, according to physician and patient choice. Treatment with adjuvant osimertinib requires selection of patients based on the presence of an EGFR-TKI sensitizing mutation. Other targeted agents are currently being evaluated in the adjuvant and neoadjuvant settings. Approval of at least some of these other agents is highly likely in the coming years, bringing with it in parallel, a requirement for comprehensive molecular testing for stage I-III disease. In this review, we consider the implications of integrating molecular testing into practice when managing patients with stage I-III non-squamous NSCLC. We discuss best practices, approaches and challenges from pathology, surgical and oncology perspectives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据